Objective: This study aimed to investigate the safety of vericiguat in patients with coronary artery disease.
Methods: We conducted a comprehensive literature review of the PubMed, ClinicalTrials.gov, and Cochrane Library databases up to 27 March 2024. We included studies that compared vericiguat with placebo in patients with coronary artery disease. Clinical data were extracted, and adverse events were analyzed using Review Manager software (version 5.4) after conducting a quality assessment of the enrolled studies.
Results: Three randomized controlled trials involving 151 patients were included in this meta-analysis. Compared with the placebo group, vericiguat treatment resulted in a decrease in systolic blood pressure by 1.4-10 mmHg and diastolic blood pressure by 0.4-6 mmHg, along with an increase in heart rate by 1.8-7 bpm, all of which are clinically insignificant. Vericiguat treatment demonstrated no significant serious adverse events [odds ratio (OR) = 1.97; 95% confidence interval (CI) = 0.39-9.91; P = 0.41]. However, a significant difference in adverse events between the two groups was noted (OR = 4.04; 95% CI = 2.17-7.52; P < 0.001).
Conclusion: This meta-analysis suggests that vericiguat is a safe drug for use in patients with coronary artery disease; however, further clinical trials are needed to validate these findings.
Registration: The study protocol has been prospectively registered in PROSPERO (CRD42024528105).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40256-024-00701-0 | DOI Listing |
Pilot Feasibility Stud
January 2025
Advocate Christ Medical Center, Advocate Health, Oak Lawn, IL, USA.
Background: Hypertension is the leading risk factor for cardiovascular disease (CVD). Despite advances in blood pressure management, significant racial and ethnic disparities persist, resulting in higher risks of stroke, heart disease, and mortality among non-White populations. Self-measured blood pressure (SMBP) monitoring, also known as home blood pressure monitoring, has shown promise in improving blood pressure control, especially when combined with feedback from healthcare providers.
View Article and Find Full Text PDFDiabetol Metab Syndr
January 2025
Department of Cardiology, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, 430074, Hubei, China.
Background: The triglyceride glucose-body mass index (TyG-BMI) is considered to be a reliable surrogate marker of insulin resistance (IR). However, limited evidence exists regarding its association with the severity of coronary artery disease (CAD), particularly in hypertensive patients with different glucose metabolic states, including those with H-type hypertension. This study aimed to investigate the relationship between TyG-BMI and CAD severity across different glucose metabolism conditions.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Cardiology Bichat, AP-HP, Paris, France.
Objectives: Transcatheter edge-to-edge repair (TEER) is an alternative for patients with severe degenerative mitral regurgitation (MR). The objective of this study was to compare the outcomes of surgery and TEER in older patients with degenerative MR patients using real life data.
Methods: Consecutives older patients (≥ 65 years-old), with severe symptomatic, degenerative MR requiring surgery or TEER between 2013 and 2023 were included.
BMC Nurs
January 2025
Department of Nursing, Jahrom University of Medical Sciences, Jahrom, Iran.
Background: Nursing care is important and necessary for Acute Coronary Syndrome patients who have undergone angiography and stenting, to minimize complications. The purpose of this study was to assess the effects of High-Quality Nursing Interventions on the quality of life and cardiac index of Acute Coronary Syndrome patients, treated with drug-eluting stents.
Methods: In this randomized trial, 70 patients of the cardiac intensive care units in one of Jahrom university of medical sciences hospitals (Iran) were selected from July 2023 to October 2023 by the available method, and randomly allocated (stochastic assignment) to two intervention (High-Quality Nursing Interventions) and control groups (routine nursing care).
Virol J
January 2025
Department of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Organ transplant recipients face a substantial risk of developing posttransplant lymphoproliferative disorders (PTLD). In over 90% of cases with B-cell PTLD following solid organ transplantation, the Epstein-Barr virus (EBV) genome is promptly identified, usually within the initial year. A continuing discussion revolves around the efficacy of antiviral prophylaxis in mitigating the incidence of PTLD in solid organ transplant (SOT) patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!